Entity

Time filter

Source Type

PARK CITY, UT, United States

Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2014

DESCRIPTION (provided by applicant): Human African trypanosomiasis (HAT) is an infectious disease with a large global health burden occurring primarily in Central and Eastern Africa. HAT is 100% fatal if untreated and the current drug therapies suffer frompoor safety profiles, difficult treatment regimens, limited effectiveness, and high costs. Furthermore, drugs that cross the blood brain barrier (BBB) are notoriously difficult to develop and have a lower probability of reaching the market place. Here, wepropose to apply a quantum-similarity approach to discover novel T. Brucei inhibitors. The approach allows for simultaneous interrogation of multiple targets and pathways, and for incorporation of various pharmacological requirements early in the discovery process, thus increasing the chances of finding novel therapeutics with great selectivity, potency and pharmacokinetic properties. Instead of screening millions of compounds for novel modulators of the target of interest, our focused testing of 10-2


Gradient Biomodeling, Llc | Entity website

A Quantum Physics Search for Liver-Stage AntimalarialsThe project is a collaboration with Dr. David Sullivan of the Johns Hopkins Bloomberg School of Public Health andsponsoredby the Grand Challenges in Global Health initiative of the Gates Foundation


Gradient Biomodeling, Llc | Entity website

Formation ofNeuRho Farmaceutica, Inc.NeuRho Farmaceutica, Inc ...


Gradient Biomodeling, Llc | Entity website

Recent site activity 9 May 2016, 12:20 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 12:18 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 12:15 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 12:12 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 12:09 Gradient Biomodeling edited about us 9 May 2016, 12:08 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 07:24 Gradient Biomodeling edited about us 9 May 2016, 07:12 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 07:07 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:55 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:50 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:48 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:46 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:46 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:45 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:45 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:44 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:40 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:38 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:37 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:36 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:36 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:36 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:35 Gradient Biomodeling edited Gradient Bulgaria 9 May 2016, 06:33 Gradient Biomodeling edited Gradient Bulgaria


Gradient Biomodeling, Llc | Entity website

Gradient Biomodeling, LLC has developed a versatile computational platform for modeling of biomolecular interactions and pathways.Applications of our technology include drug discovery and design, repositioning of therapeutic compounds, small-molecule diagnostics, chemical genetics, biomarker identification, etc

Discover hidden collaborations